Your session is about to expire
← Back to Search
Regimen 5 for Eosinophilic Esophagitis
Study Summary
This trial tests a new drug to see if it is safe & effective at treating EoE in healthy people & patients with the condition.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are individuals aged 50 or older eligible for this research project?
"This research project is looking for volunteers aged between 18 and 65 years old."
Has the U.S. Food & Drug Administration sanctioned Regimen 5?
"Our experts at Power assessed the safety of Regimen 5 as a 1, taking into account that this is an early phase trial with limited data available to support its efficacy and safety."
What is the current enrollment for this clinical experimentation?
"Affirmative. The information available on clinicaltrials.gov alludes to this medical trial recruiting participants at the present moment. This particular experiment was initially published on January 20th, 2023 and has since been updated on February 23rd, 2023 with a goal of enrolling 24 patients from one facility."
Does my profile meet the selection criteria for this research endeavor?
"Those who wish to be included in this medical study must have a diagnosis of eosinophilic esophagitis and fall within the age bracket of 18-65 years old. The trial is set to accept 24 participants."
Is enrollment for this research study still open to participants?
"Affirmative. The details presented on clinicaltrials.gov suggest that recruitment for this research study is still underway, with 24 individuals required to be selected from a single site since the initial posting date of January 20th 2023 and most recent update occurring February 23rd 2023."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger